Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France
Patients with cancer have an increased risk of developing venous thromboembolism (VTE) and an increased risk of death from VTE. Until recently, the standard of care for treatment of VTE in cancer patients was low molecular weight heparins (LMWH). To determine treatment patterns and outcomes, we perf...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/11/3011 |
| _version_ | 1797597794327855104 |
|---|---|
| author | Laurent Bertoletti Gaelle Gusto Nadia Quignot Artak Khachatryan Jose Chaves Audrey Moniot Ruth Mokgokong Isabelle Mahé |
| author_facet | Laurent Bertoletti Gaelle Gusto Nadia Quignot Artak Khachatryan Jose Chaves Audrey Moniot Ruth Mokgokong Isabelle Mahé |
| author_sort | Laurent Bertoletti |
| collection | DOAJ |
| description | Patients with cancer have an increased risk of developing venous thromboembolism (VTE) and an increased risk of death from VTE. Until recently, the standard of care for treatment of VTE in cancer patients was low molecular weight heparins (LMWH). To determine treatment patterns and outcomes, we performed an observational study using a nationwide health database. Treatment patterns, rates of bleeding, and VTE recurrence at 6 and 12 months were assessed in cancer patients with VTE in France prescribed LMWH in 2013–2018. Of 31,771 patients administered LMWH (mean age 66.3 years), 51.0% were male, 58.7% had pulmonary embolism, and 70.9% had metastatic disease. At 6 months LMWH persistence was 81.6%, VTE recurrence had occurred in 1256 patients (4.0%) at a crude rate per 100 person-months (PM) of 0.90, and bleeding had occurred in 1124 patients (3.5%) at a crude rate per 100 PM of 0.81. At 12 months, VTE recurrence had occurred in 1546 patients (4.9%) at a crude rate per 100 PM of 0.71 and bleeding had occurred in 1438 patients (4.5%) at a crude rate per 100 PM of 0.66. Overall, VTE-related clinical event rates were high among patients administered LMWH, suggesting an unmet medical need. |
| first_indexed | 2024-03-11T03:10:29Z |
| format | Article |
| id | doaj.art-53a49810248045e59198aff2b0717105 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T03:10:29Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-53a49810248045e59198aff2b07171052023-11-18T07:39:30ZengMDPI AGCancers2072-66942023-05-011511301110.3390/cancers15113011Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in FranceLaurent Bertoletti0Gaelle Gusto1Nadia Quignot2Artak Khachatryan3Jose Chaves4Audrey Moniot5Ruth Mokgokong6Isabelle Mahé7Université Jean Monnet Saint-Étienne, CHU Saint-Étienne, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, CIC 1408, Département of Médecine Vasculaire et Thérapeutique, F-42023 Saint-Etienne, FranceCertara France, 75008 Paris, FranceCertara France, 75008 Paris, FranceCertara UK, London EC2Y 5EB, UKPfizer SLU, 28108 Madrid, SpainPfizer SAS, Pfizer, 75668 Paris, FrancePfizer Ltd., Tadworth KT20 7NS, UKInnovations Thérapeutiques en Hémostase, Service de Médecine Interne, APHP, Inserm UMR_S1140, Hôpital Louis Mourier, Université Paris Cité, 75015 Paris, FrancePatients with cancer have an increased risk of developing venous thromboembolism (VTE) and an increased risk of death from VTE. Until recently, the standard of care for treatment of VTE in cancer patients was low molecular weight heparins (LMWH). To determine treatment patterns and outcomes, we performed an observational study using a nationwide health database. Treatment patterns, rates of bleeding, and VTE recurrence at 6 and 12 months were assessed in cancer patients with VTE in France prescribed LMWH in 2013–2018. Of 31,771 patients administered LMWH (mean age 66.3 years), 51.0% were male, 58.7% had pulmonary embolism, and 70.9% had metastatic disease. At 6 months LMWH persistence was 81.6%, VTE recurrence had occurred in 1256 patients (4.0%) at a crude rate per 100 person-months (PM) of 0.90, and bleeding had occurred in 1124 patients (3.5%) at a crude rate per 100 PM of 0.81. At 12 months, VTE recurrence had occurred in 1546 patients (4.9%) at a crude rate per 100 PM of 0.71 and bleeding had occurred in 1438 patients (4.5%) at a crude rate per 100 PM of 0.66. Overall, VTE-related clinical event rates were high among patients administered LMWH, suggesting an unmet medical need.https://www.mdpi.com/2072-6694/15/11/3011venous thromboembolismcanceranticoagulantsbleedinglow molecular weight heparinmedical database |
| spellingShingle | Laurent Bertoletti Gaelle Gusto Nadia Quignot Artak Khachatryan Jose Chaves Audrey Moniot Ruth Mokgokong Isabelle Mahé Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France Cancers venous thromboembolism cancer anticoagulants bleeding low molecular weight heparin medical database |
| title | Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France |
| title_full | Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France |
| title_fullStr | Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France |
| title_full_unstemmed | Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France |
| title_short | Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France |
| title_sort | low molecular weight heparin treatment patterns and outcomes in cancer patients with acute venous thromboembolism a nationwide cohort study in france |
| topic | venous thromboembolism cancer anticoagulants bleeding low molecular weight heparin medical database |
| url | https://www.mdpi.com/2072-6694/15/11/3011 |
| work_keys_str_mv | AT laurentbertoletti lowmolecularweightheparintreatmentpatternsandoutcomesincancerpatientswithacutevenousthromboembolismanationwidecohortstudyinfrance AT gaellegusto lowmolecularweightheparintreatmentpatternsandoutcomesincancerpatientswithacutevenousthromboembolismanationwidecohortstudyinfrance AT nadiaquignot lowmolecularweightheparintreatmentpatternsandoutcomesincancerpatientswithacutevenousthromboembolismanationwidecohortstudyinfrance AT artakkhachatryan lowmolecularweightheparintreatmentpatternsandoutcomesincancerpatientswithacutevenousthromboembolismanationwidecohortstudyinfrance AT josechaves lowmolecularweightheparintreatmentpatternsandoutcomesincancerpatientswithacutevenousthromboembolismanationwidecohortstudyinfrance AT audreymoniot lowmolecularweightheparintreatmentpatternsandoutcomesincancerpatientswithacutevenousthromboembolismanationwidecohortstudyinfrance AT ruthmokgokong lowmolecularweightheparintreatmentpatternsandoutcomesincancerpatientswithacutevenousthromboembolismanationwidecohortstudyinfrance AT isabellemahe lowmolecularweightheparintreatmentpatternsandoutcomesincancerpatientswithacutevenousthromboembolismanationwidecohortstudyinfrance |